God livskvalitet målet med vård och omhändertagande vid ALS - Enda sjukdomsmodifierande läkemedlet har begränsad effekt
(2020) In Läkartidningen 117.- Abstract
ALS is characterized by the degeneration of upper and lower motor neurons. In about 70% of patients with ALS the disease has an spinal onset, while about 30% of the patients have a bulbar onset. Cognitive dysfunction and behavioral changes are seen in about 50% of the patients, and 15% develop frontotemporal dementia. There is no single test that provides the ALS diagnosis. The diagnosis is based on clinical and electrophysiological signs, and the exclusion of other diseases. The only disease modulating treatment approved for ALS in Sweden is Riluzole, sadly only with limited effect. Other treatments are symptomatic and the goal is to help patients achieve the best possible quality of life through multidiciplinary ALS teams.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/e2be9126-519b-49ec-8a4e-8124059719cb
- author
- Ingre, Caroline ; Nygren, Ingela ; Zachau, Anne and Staaf, Gert LU
- alternative title
- Quality of life the goal of care for patients with ALS
- publishing date
- 2020-03-10
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Läkartidningen
- volume
- 117
- article number
- FX4H
- publisher
- Swedish Medical Association
- external identifiers
-
- pmid:32154900
- scopus:85081648329
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- no
- id
- e2be9126-519b-49ec-8a4e-8124059719cb
- alternative location
- https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/temaartikel/2020/03/god-livskvalitet-malet-med-vard-och-omhandertagande-vid-als/
- date added to LUP
- 2020-04-01 14:21:12
- date last changed
- 2022-04-18 21:40:28
@article{e2be9126-519b-49ec-8a4e-8124059719cb,
abstract = {{<p>ALS is characterized by the degeneration of upper and lower motor neurons. In about 70% of patients with ALS the disease has an spinal onset, while about 30% of the patients have a bulbar onset. Cognitive dysfunction and behavioral changes are seen in about 50% of the patients, and 15% develop frontotemporal dementia. There is no single test that provides the ALS diagnosis. The diagnosis is based on clinical and electrophysiological signs, and the exclusion of other diseases. The only disease modulating treatment approved for ALS in Sweden is Riluzole, sadly only with limited effect. Other treatments are symptomatic and the goal is to help patients achieve the best possible quality of life through multidiciplinary ALS teams.</p>}},
author = {{Ingre, Caroline and Nygren, Ingela and Zachau, Anne and Staaf, Gert}},
issn = {{0023-7205}},
language = {{swe}},
month = {{03}},
publisher = {{Swedish Medical Association}},
series = {{Läkartidningen}},
title = {{God livskvalitet målet med vård och omhändertagande vid ALS - Enda sjukdomsmodifierande läkemedlet har begränsad effekt}},
url = {{https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/temaartikel/2020/03/god-livskvalitet-malet-med-vard-och-omhandertagande-vid-als/}},
volume = {{117}},
year = {{2020}},
}